---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093339"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:58:35.493751+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intellia Q2 net loss widens to $147M; NTLA-2002 Phase 2 meets endpoints, Phase 3 on track

## Summary
- NTLA-2002 Phase 2 for HAE met primary and all secondary endpoints; 50 mg dose selected for pivotal Phase 3, on track to start 2H 2024.
- Phase 3 MAGNITUDE trial (NTLA-2001 for ATTR-CM) enrolling rapidly across >12 countries and >35 sites.
- Plans to initiate Phase 3 of NTLA-2001 for ATTRv-PN by year-end and dose first patient in NTLA-3001 Phase 1/2 for AATD in 2H 2024.
- Q2 2024 net loss $147.0M vs $123.7M YoY; cash $939.9M expected to fund operations into late 2026.
- Appointed Edward Dulac as CFO effective July 22 and Brian Goff to board of directors.

## SEC filing metadata
- accession: 0000950170-24-093339
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017024093339/0000950170-24-093339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017024093339/ntla-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093339
- JSON: https://secwatch.observer/filing/0000950170-24-093339.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.